FirstString Research

FirstString Research is a clinical-stage biotechnology company dedicated to transforming cell-cell communication and cell-cell contact/adhesion science into a pipeline for drug and medical applications aimed at preventing scars, reducing inflammation, wound healing, and complex tissue regeneration. The company holds an exclusive global license from the Medical University of South Carolina (MUSC) for the connexin technology platform and intellectual property related to a combination of peptides capable of modulating connexins, which are crucial for intercellular communication. Phase I human clinical trials have demonstrated the safety and efficacy of the lead peptide generated by this technology platform.